Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca has announced that as of 31 October 2025, its issued share capital with voting rights consists of 1,550,712,906 ordinary shares, with none held in Treasury. This figure is crucial for shareholders to determine their notification obligations under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting shareholder engagement and regulatory compliance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £142.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors contributing to the score. The technical analysis suggests caution due to potential overbought conditions, and the valuation indicates a premium price. Despite some challenges, the company’s robust pipeline and strategic growth initiatives support a positive outlook.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines, particularly in the fields of Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are available in over 125 countries and are used by millions of patients worldwide.
Average Trading Volume: 2,130,310
Technical Sentiment Signal: Buy
Current Market Cap: £193.3B
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.